{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:03:49Z","timestamp":1770491029156,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010273","name":"Roberto and Cornelia Pallotti's Legacy for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.prp.2020.153012","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T10:23:05Z","timestamp":1590315785000},"page":"153012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer"],"prefix":"10.1016","volume":"216","author":[{"given":"Tania","family":"Franceschini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Capizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Schiavina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelangelo","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2020.153012_bib0005","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"Moch","year":"2015"},{"issue":"Suppl 2","key":"10.1016\/j.prp.2020.153012_bib0010","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2020.153012_bib0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/PAP.0b013e31817d79b9","article-title":"The many faces of urothelial carcinoma: an update with an emphasis on recently described variants","volume":"15","author":"Nigwekar","year":"2008","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.prp.2020.153012_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.prp.2020.153012_bib0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/00000478-199412000-00005","article-title":"Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma","volume":"18","author":"Amin","year":"1994","journal-title":"Am. J. Surg. Pathol."},{"issue":"Dec. (4)","key":"10.1016\/j.prp.2020.153012_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.path.2018.07.011","article-title":"Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants","volume":"11","author":"Al-Ahmadie","year":"2018","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.prp.2020.153012_bib0035","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2020.153012_bib0040","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"National cancer institute: trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2020.153012_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Sep. (3)","key":"10.1016\/j.prp.2020.153012_bib0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11523-014-0341-x","article-title":"Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"Target. Oncol."},{"issue":"July","key":"10.1016\/j.prp.2020.153012_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum. Pathol."},{"issue":"20","key":"10.1016\/j.prp.2020.153012_bib0060","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"Feb. (2)","key":"10.1016\/j.prp.2020.153012_bib0065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10620-013-2925-1","article-title":"HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer","volume":"59","author":"Ma","year":"2014","journal-title":"Dig. Dis. Sci."},{"issue":"Apr. (3)","key":"10.1016\/j.prp.2020.153012_bib0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","article-title":"Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma","volume":"4","author":"Behzato\u011flu","year":"2018","journal-title":"Eur. Urol. Focus"},{"issue":"October","key":"10.1016\/j.prp.2020.153012_bib0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"Zinnall","year":"2018","journal-title":"Hum. Pathol."},{"issue":"Jun. (6)","key":"10.1016\/j.prp.2020.153012_bib0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","article-title":"Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer","volume":"466","author":"Tschui","year":"2015","journal-title":"Virchows Arch."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382030546X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382030546X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:42:04Z","timestamp":1759732924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403382030546X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S034403382030546X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2020.153012","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2020.153012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153012"}}